Tango Therapeutics (NASDAQ:TNGX) granted equity awards under its 2023 Inducement Plan, effective June 1, 2026, pursuant to Nasdaq Rule 5635(c)(4).
A new employee received a non-qualified option for 170,000 shares at an exercise price of $23.10 and 40,000 RSUs, with multi‑year vesting tied to continued employment.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – TNGX
-8.71%
-8.71%Session close to close
In the Jun 5 session, TNGX declined 8.71%, reflecting a notable negative market reaction.
The stock moved -8.7% in the session following this news. A negative reaction despite the largely ad...
Analysis
The stock moved -8.7% in the session following this news. A negative reaction despite the largely administrative nature of this inducement grant would fit a pattern where even neutral news sometimes coincided with pullbacks after prior events. The grant adds 170,000 options and 40,000 RSUs but does not change Tango’s reported cash runway into 2028 or late-stage plans for vopimetostat. Investors may also contextualize moves against the existing resale registration filed in 2025.
Key Figures
Stock option grant:170,000 sharesRSU grant:40,000 RSUsExercise price:$23.10 per share+5 more
8 metrics
Stock option grant170,000 sharesNon-qualified stock option to new employee under 2023 Inducement Plan
RSU grant40,000 RSUsRestricted stock units granted to new employee as inducement
Exercise price$23.10 per shareOption strike, equal to TNGX closing price on June 1, 2026
Initial vesting25% of sharesOptions vest 25% on first anniversary of employee start date
Subsequent vesting1/36th monthlyRemaining option shares vest monthly over three years thereafter
RSU vesting schedule3 equal annual installmentsRSUs vest annually, subject to continued employment
Nasdaq ruleRule 5635(c)(4)Basis for inducement equity awards for new employees
Plan approval dateFebruary 2023Tango Therapeutics 2023 Inducement Plan approval timing
Reported FY 2025 results, strong cash, and plans for pivotal vopimetostat study.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news events, including earnings, leadership changes, and prior inducement grants, have largely seen price moves that align directionally with the tone of the announcements.
Recent Company History
Over the past few months, Tango has focused on strengthening its balance sheet and advancing its oncology pipeline. Earnings updates on Mar 5 and May 13 highlighted cash balances above $343M and funding visibility into 2028, alongside plans for a pivotal vopimetostat study and multiple 2026 data readouts. Leadership appointments on Apr 15 supported late-stage development efforts. The company also repeatedly used its 2023 Inducement Plan to grant equity to new hires, with prior inducement grants on Mar 6 and May 4 showing generally aligned price reactions.
Key Terms
non-qualified stock option, restricted stock units (RSUs), inducement plan, Nasdaq Listing Rules, +1 more
5 terms
non-qualified stock optionfinancial
"granted a non-qualified stock option to purchase 170,000 shares of its common stock"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
restricted stock units (RSUs)financial
"and 40,000 restricted stock units (RSUs) to a new employee under"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
Nasdaq Listing Rulesregulatory
"pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules."
Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.
stock optionfinancial
"The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
BOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective June 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 170,000 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.
The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The options have an exercise price of $23.10 per share, which is equal to the closing price of Tango Therapeutics' common stock on June 1, 2026. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the employee’s start date and as to an additional 1/36th of the remaining shares underlying the option monthly thereafter, in each case, subject to each such employee's continued employment on each vesting date. The RSU award will vest in three equal annual installments, subject to the employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.
AboutTangoTherapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
What equity awards did Tango Therapeutics (TNGX) grant on June 1, 2026?
Tango Therapeutics granted a stock option for 170,000 shares and 40,000 RSUs to a new employee. According to Tango Therapeutics, these awards were issued under the 2023 Inducement Plan as a material inducement for the individual to enter employment.
What is the exercise price of the new Tango Therapeutics (TNGX) stock option grant?
The new Tango Therapeutics stock option has an exercise price of $23.10 per share. According to Tango Therapeutics, this price equals the closing price of its common stock on June 1, 2026, when the option was granted.
How do Tango Therapeutics (TNGX) inducement stock options granted in June 2026 vest?
The inducement stock options vest 25% on the first anniversary of the employee’s start date. According to Tango Therapeutics, the remaining 75% vests in 36 equal monthly installments, subject to the employee’s continued employment on each vesting date.
What is the vesting schedule for the 40,000 RSUs granted by Tango Therapeutics (TNGX)?
The 40,000 RSUs vest in three equal annual installments over three years. According to Tango Therapeutics, each installment is subject to the employee’s continued employment on the applicable vesting date, under the terms of the 2023 Inducement Plan.
Under which plan and rule were Tango Therapeutics (TNGX) June 2026 inducement grants issued?
The June 2026 inducement grants were issued under the Tango Therapeutics 2023 Inducement Plan. According to Tango Therapeutics, this plan is used solely for inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4) and was approved in February 2023.
